Last month, it was made known that Bayer and Johnson & Johnson, the companies responsible for manufacturing the blood thinner Xarelto, are pushing for additional FDA approvals for their drug. Xarelto is already being prescribed to patients to treat blood clots, such as deep-vein thrombosis (DVT) and pulmonary embolus (PE), that occur more frequently in patients who have had certain types of surgeries, like knee and hip replacements. Now, the companies want the FDA to approve the use of the drug in stroke patients.
Bayer and Johnson & Johnson are pushing for this new approval, even after lawsuits against them have already been consolidated against them in two U.S. courts. Currently, Xarelto is leading sales and has captured the largest share of the market, raking in $1.5 billion in sales in 2013 alone. By soliciting more approvals, the companies are essentially attempting to increase profits, even while hundreds of patients hurt by Xarelto are taking legal action against them. A new trial, called the NAVIGATE-ESUS study, will include 7,000 patients and will focus on whether or not Xarelto is a better and safer alternative to aspirin for patients susceptible to strokes.
Legal Commentary
Xarelto attorneys within our firm are studying, examining and investigating current Xarelto claims on behalf of people or families injured by the drug. Some of the side effects include hemorrhaging, internal bleeding, stroke and or death. If you or a loved one has experienced any side effects while taking Xarelto, contact our Xarelto lawyers to discuss the facts of your potential case. We are available by phone for a free consultation at 1.866.705.7584 or by email at mn@fnlawfirm.com.
About the Author
Majed Nachawati is a dedicated Xarelto Lawyer with a focus on representing victims and families harmed by this dangerous drug on a nationwide basis. Mr. Nachawati has resolved numerous dangerous drug medication cases through trial and settlement that have resulted in seven and eight figure confidential settlements. He is on the Grievance Committee for the State Bar of Texas. He is licensed to practice in the Northern, Southern, and Eastern Districts of Texas. Mr. Nachawati is a member of the Board of Directors of the Texas Trial Lawyers Association, the Board of Directors for Public Justice, a Leaders’ Forum and PAC member of the American Association for Justice. Mr. Nachawati has been recognized as a Super Lawyer in Texas Monthly Magazine for the past six consecutive years for legal excellence, in connection with noteworthy settlements for pharmaceutical injury cases. Mr. Nachawati is also a member of The Million Dollar Advocates Forum. Mr. Nachawati can be reached by email at mn@fnlawfirm.com or by calling 1.866.705.7584.